SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE M impact

FDA accepts Intellia biologics license application for priority review

Intellia Therapeutics said the U.S. FDA has accepted its biologics license application for lonvoguran ziclumeran (Lonvo-z) for hereditary angioedema (HAE) and granted priority review.

NTLA

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a biopharmaceutical company focused on CRISPR gene editing and other core technologies, said the U.S. Food and Drug Administration has accepted…

Related stories